487 related articles for article (PubMed ID: 19996983)
1. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.
Low K; Hwang L; Hua J; Zhu A; Morales W; Pimentel M
J Clin Gastroenterol; 2010 Sep; 44(8):547-50. PubMed ID: 19996983
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic treatment of constipation-predominant irritable bowel syndrome.
Pimentel M; Chang C; Chua KS; Mirocha J; DiBaise J; Rao S; Amichai M
Dig Dis Sci; 2014 Jun; 59(6):1278-85. PubMed ID: 24788320
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
4. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Pimentel M; Chatterjee S; Chow EJ; Park S; Kong Y
Dig Dis Sci; 2006 Aug; 51(8):1297-301. PubMed ID: 16832617
[TBL] [Abstract][Full Text] [Related]
5. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
Bae S; Lee KJ; Kim YS; Kim KN
J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
[TBL] [Abstract][Full Text] [Related]
6. Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
Kasir R; Zakko S; Zakko P; Adler M; Lee A; Dhingra S; Guttermuth C
Dig Dis Sci; 2016 Mar; 61(3):846-51. PubMed ID: 26362282
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
Meyrat P; Safroneeva E; Schoepfer AM
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911
[TBL] [Abstract][Full Text] [Related]
8. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study.
Pimentel M; Chow EJ; Lin HC
Am J Gastroenterol; 2003 Feb; 98(2):412-9. PubMed ID: 12591062
[TBL] [Abstract][Full Text] [Related]
9. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
[TBL] [Abstract][Full Text] [Related]
10. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Majewski M; McCallum RW
Adv Med Sci; 2007; 52():139-42. PubMed ID: 18217406
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.
Yang J; Lee HR; Low K; Chatterjee S; Pimentel M
Dig Dis Sci; 2008 Jan; 53(1):169-74. PubMed ID: 17520365
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW
Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166
[TBL] [Abstract][Full Text] [Related]
13. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution.
Parodi A; Dulbecco P; Savarino E; Giannini EG; Bodini G; Corbo M; Isola L; De Conca S; Marabotto E; Savarino V
J Clin Gastroenterol; 2009; 43(10):962-6. PubMed ID: 19525858
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.
Collins BS; Lin HC
J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):382-6. PubMed ID: 21240023
[TBL] [Abstract][Full Text] [Related]
15. [Variation of intestinal fermentative profile after sequential therapy with rifaximin/probiotics].
Dima G; Peralta D; Novillo A; Lasa J; Besasso H; Soifer L
Acta Gastroenterol Latinoam; 2012 Jun; 42(2):99-104. PubMed ID: 22876711
[TBL] [Abstract][Full Text] [Related]
16. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
[TBL] [Abstract][Full Text] [Related]
17. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
18. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.
Scarpellini E; Gabrielli M; Lauritano CE; Lupascu A; Merra G; Cammarota G; Cazzato IA; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2007 Apr; 25(7):781-6. PubMed ID: 17373916
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
[TBL] [Abstract][Full Text] [Related]
20. Does Carbohydrate Challenge Testing Predict Clinical Response in Small Intestinal Bacterial Overgrowth?
Long SK; Di Palma JA
South Med J; 2016 May; 109(5):296-9. PubMed ID: 27135726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
